Jasper Therapeutics (JSPR) News Today $22.05 +0.21 (+0.96%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaNovember 18, 2024 | seekingalpha.comWe're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn RateNovember 17, 2024 | sg.finance.yahoo.comIs Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comBrokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $74.86November 15, 2024 | americanbankingnews.comJasper Therapeutics to Participate at Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month target price among brokeragesNovember 12, 2024 | marketbeat.comJasper Therapeutics (JSPR) Gets a Buy from RBC CapitalNovember 9, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)November 9, 2024 | markets.businessinsider.comAnalysts Bullish on Jasper Therapeutics as Briquilimab Trials Show PromiseNovember 8, 2024 | finance.yahoo.comPositive Expectations and Clinical Success Drive Buy Rating for Jasper TherapeuticsNovember 7, 2024 | markets.businessinsider.comPromising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in BriquilimabNovember 7, 2024 | markets.businessinsider.comJasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)October 29, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Stock, Option ChainOctober 29, 2024 | benzinga.comHC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday.October 24, 2024 | marketbeat.comJasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 24, 2024 | globenewswire.comBuy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic AdvancementsOctober 24, 2024 | markets.businessinsider.comJasper Therapeutics commences open-label extension study of chronic urticariasOctober 23, 2024 | markets.businessinsider.comJasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous UrticariaOctober 23, 2024 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been given a consensus recommendation of "Buy" by the ten ratings firms that are presently covering the company, MarketBeat.com reports. Ten research analysts have rated the stock with a buy recommendation. The average 1 year target priOctober 18, 2024 | marketbeat.comJasper Therapeutics' (JSPR) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday.October 15, 2024 | marketbeat.comBuy Rating Affirmed for Jasper Therapeutics Amidst Promising Briquilimab Clinical Data and Market PotentialOctober 15, 2024 | markets.businessinsider.comBuy Rating Maintained on Jasper Therapeutics Amid Promising Briquilimab Efficacy and Favorable Side Effect ProfileOctober 15, 2024 | markets.businessinsider.comJasper Therapeutics Reports Positive Data From SPOTLIGHT Study - Quick FactsOctober 15, 2024 | markets.businessinsider.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaOctober 14, 2024 | finanznachrichten.deJasper Therapeutics Stock Gains on Strong Briquilimab Trial ResultsOctober 14, 2024 | marketwatch.comPromising SPOTLIGHT Study Results Support Buy Rating for Jasper Therapeutics Amid Briquilimab’s CIndU Treatment SuccessOctober 14, 2024 | markets.businessinsider.comJasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaOctober 14, 2024 | globenewswire.comJasper Therapeutics (JSPR) Gets a Buy from OppenheimerOctober 1, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comJasper Therapeutics (NASDAQ:JSPR) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comBuy Recommendation: Jasper Therapeutics’ Briquilimab Shows Market Edge with Favorable Safety ProfileSeptember 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jasper Therapeutics Amid Promising Briquilimab Prospects and Strategic DevelopmentSeptember 27, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Friday.September 27, 2024 | marketbeat.comBuy Rating on Jasper Therapeutics Focused on Briquilimab’s Efficacy with Reduced ToxicitySeptember 26, 2024 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLCAlly Bridge Group NY LLC trimmed its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 24.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,614 shares of the company's stockSeptember 23, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of "Buy" by BrokeragesJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received a consensus rating of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that havSeptember 23, 2024 | marketbeat.comShort Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Increases By 8.7%Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,000,000 shares, a growth of 8.7% from the August 15th total of 1,840,000 shares. Based on an average daily volume of 188,600 shares, the short-interest ratio is presently 10.6 days. Approximately 17.3% of the shares of the stock are sold short.September 18, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockSeptember 13, 2024 | insidertrades.comJasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $19,107.00 in StockJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) COO Jeetinder Singh Mahal sold 900 shares of the firm's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $21.23, for a total transaction of $19,107.00. Following the sale, the chief operating officer now owns 25,009 shares in the company, valued at $530,941.07. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.September 12, 2024 | marketbeat.comJasper Therapeutics stock set for growth with novel stem cell therapy - JMPSeptember 11, 2024 | investing.comJasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in AsthmaSeptember 10, 2024 | globenewswire.comCantor Fitzgerald Reiterates "Overweight" Rating for Jasper Therapeutics (NASDAQ:JSPR)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday.September 9, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Now Covered by JMP SecuritiesJMP Securities initiated coverage on Jasper Therapeutics in a research report on Monday. They set an "outperform" rating and a $70.00 target price on the stock.September 9, 2024 | marketbeat.comBuy Rating Justified by Jasper Therapeutics’ Innovative c-Kit Targeting Treatments and Market PotentialSeptember 9, 2024 | markets.businessinsider.comJasper Therapeutics to Present at Present at Upcoming September Investor ConferencesSeptember 4, 2024 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of "Buy" by AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned a consensus recommendation of "Buy" from the nine analysts that are currently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 1-year price target among brokerAugust 29, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by Evercore ISIEvercore ISI restated an "outperform" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday.August 26, 2024 | marketbeat.comJasper Therapeutics (JSPR) Gets a Buy from Stifel NicolausAugust 19, 2024 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Large Growth in Short InterestJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 1,640,000 shares, an increase of 40.2% from the July 15th total of 1,170,000 shares. Currently, 15.0% of the company's stock are sold short. Based on an average trading volume of 161,800 shares, the short-interest ratio is presently 10.1 days.August 15, 2024 | marketbeat.com Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week watch this FREE briefing with me and expert trader Graham Lindman JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼0.150.49▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼32▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DocGo News Momentus News Arcus Biosciences News ARS Pharmaceuticals News Ardelyx News Arcutis Biotherapeutics News Calliditas Therapeutics AB (publ) News Rocket Pharmaceuticals News ANI Pharmaceuticals News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts